PP
ADVM

Paloma Partners’s Adverum Biotechnologies ADVM Stock Holding History

Paloma Partners’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,408
Closed -$152K – 1993
2020
Q4 		$152K Buy
+1,408
New +$174K ﹤0.01% 1451
2020
Q1 		– Sell
-5,539
Closed -$638K – 1186
2019
Q4 		$638K Sell
5,539
-2,784
-33% -$245K 0.01% 1243
2019
Q3 		$454K Buy
+8,323
New +$938K 0.01% 1231
2017
Q3 		– Sell
-16,510
Closed -$413K – 2062
2017
Q2 		$413K Buy
16,510
+6,510
+65% +$178K ﹤0.01% 1648
2017
Q1 		$270K Buy
10,000
+8,092
+424% +$230K ﹤0.01% 1772
2016
Q4 		$55K Buy
+1,908
New +$62.4K ﹤0.01% 1924

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Paloma Partners's ADVM Position: Q1 2021 in Review

Paloma Partners sold out of Adverum Biotechnologies (ADVM) in Q1 2021, closing a stake of 1,408 shares — an estimated $152K sold.

Paloma Partners first reported a position in ADVM in Q4 2016 and held it in 6 quarters. The position peaked at $638K in Q4 2019. 132 funds tracked by Wall St. Rank hold ADVM as of Q1 2021.

  • Paloma Partners reported no remaining Adverum Biotechnologies position as of Q1 2021 after selling out during the quarter.
  • Paloma Partners sold 1,408 Adverum Biotechnologies shares in Q1 2021, an estimated $152K.
  • Paloma Partners first reported a position in Adverum Biotechnologies in Q4 2016 and held it in 6 quarters.
  • Paloma Partners's Adverum Biotechnologies position peaked at $638K in Q4 2019.
  • 132 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2021.

Based on Paloma Partners's 13F filing for Q1 2021, filed 17 May 2021.